Lixisenatide clinical trials
Also written Lyxumia.
How each study uses lixisenatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lixisenatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Jul 2016 · ADLYXIN · BLA 208471 (FDA, Drugs@FDA)
- European Union
- 31 Jan 2013 · Lyxumia · EMEA/H/C/002445 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
57 studies that test it; most in 2008 (7)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 4 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 16
Sanofi (40) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University Hospital, Toulouse (1) · Population Health Research Institute (1) · University of Campania Luigi Vanvitelli (1) · University Hospital, Gentofte, Copenhagen (1) · Seoul National University Hospital (1) · Medical University of Vienna (1)
Often tested with
Tested in the same studies.
Insulin Glargine (20) · Metformin (2) · IDegLira (1) · Liraglutide (1) · Dulaglutide (1)
Studies
Open first, then newest update. How each study uses lixisenatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 57
- iGlarLixi CGM Study in Chinese T2D Individuals After OADsRecruitingPhase 4SanofiNCT06671587Written as iGlarLixi (insulin glargine/lixisenatide)How we know
- Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesEnrolling by invitationPhase 4Medical University of WarsawNCT07117240Written as lixisenatide + glargineHow we know
- The Effect of Lixisenatide on the Effect of Pituitary HormonesRecruitingPhase 4University of TartuNCT05804513Written as Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen InjectorHow we know
- Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver DiseaseActive, not recruitingPhase 4The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07274644Written as iGlarLixiHow we know
- Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseCompletedPhase 2University Hospital, ToulouseNCT03439943Written as LixisenatideHow we know
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)CompletedPhase 3SanofiNCT05413369Written as Insulin glargine/LixisenatideHow we know
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusCompletedPhase 4SanofiNCT05114590Written as Insulin glargine/LixisenatideHow we know
- Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 DiabetesStatus unknownPhase 4Chungbuk National University HospitalNCT04893148Written as IGlarLixiHow we know
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompletedPhase 3SanofiNCT03798080Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)How we know
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)CompletedPhase 3SanofiNCT03798054Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)How we know
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCompletedPhase 4SanofiNCT02941367Written as Lixisenatide (AVE0010)How we know
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)CompletedPhase 3SanofiNCT03529123Written as INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)How we know
- A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1SanofiNCT02803918Written as Lixisenatide (AVE0010)How we know
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTerminatedPhase 3SanofiNCT03434119Written as Insulin glargine/LixisenatideHow we know
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedPhase 3SanofiNCT02787551Written as Insulin glargine/lixisenatide fixed ratio combinationHow we know
- INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixiStatus unknownPhase 4Institute for Clinical and Experimental MedicineNCT04945070Written as IGlarLixiHow we know
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixiCompletedPhase 3Population Health Research InstituteNCT03130426Written as iGlarLixiHow we know
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)CompletedPhase 4University of Campania Luigi VanvitelliNCT04196231Written as IGlarLixiHow we know
- Effects of Insulin Glargine and Lixisenatide on the BrainTerminatedPhase 4University Hospital TuebingenNCT03881995Written as IGlarLixiHow we know
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompletedPhase 3SanofiNCT02752412Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)How we know
See all 57 studies that test lixisenatide →
Given beside what is tested · 1 — lixisenatide is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with lixisenatide
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMCompletedPhase 3SanofiNCT02058147Written as Lixisenatide (AVE0010)How we know
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 DiabetesCompletedPhase 4Novo Nordisk A/SNCT01973231Written as lixisenatideHow we know
Codes
What other systems call lixisenatide · ClinicalTrials.gg INT004587
- MeSH (NLM) C479460lixisenatideOne source NLM
- UNII (FDA) 74O62BB01ULIXISENATIDEConfirmed FDA, NLM
- RxNorm 1440051One source FDA
- NCI Thesaurus C166988LixisenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C479460 | lixisenatide | One source NLM |
| UNII (FDA) | 74O62BB01U | LIXISENATIDE | Confirmed FDA, NLM |
| RxNorm | 1440051 | — | One source FDA |
| NCI Thesaurus | C166988 | Lixisenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.